MARKET

CLRPF

CLRPF

Clarity Pharmaceuticals Ltd
OTCPK
1.280
+0.180
+16.36%
Closed 10:11 11/13 EST
OPEN
1.280
PREV CLOSE
1.100
HIGH
1.280
LOW
1.280
VOLUME
14.52K
TURNOVER
18.59K
52 WEEK HIGH
3.100
52 WEEK LOW
1.000
MARKET CAP
477.54M
P/E (TTM)
-6.3492
1D
5D
1M
3M
1Y
5Y
1D
No Data
About CLRPF
Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical company. The Company is focused on developing targeted copper theranostics based on its SAR Technology Platform. It is progressing clinical trials with its approximately three key products, SARTATE, SAR-bisPSMA, and SAR-Bombesin. Its lead product, SAR-bisPSMA, is progressing through over three clinical trials: one theranostic trial (SECuRE) and two Phase III diagnostic trials (CLARIFY and AMPLIFY). SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2). SAR-bisPSMA is developed for diagnosing, staging, and treating prostate cancer that expresses prostate-specific membrane antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer.

Webull offers Clarity Pharmaceuticals Ltd stock information, including OTCPK: CLRPF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLRPF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CLRPF stock methods without spending real money on the virtual paper trading platform.